about
HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cellsInfections caused by Scedosporium spp.Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7Comparison of the Abbott 7000 and Bayer 340 Systems for Measurement of Hepatitis C Virus LoadHepatitis C Viral Kinetics During Treatment With Peg IFN-alpha-2b in HIV/HCV Coinfected Patients as a Function of Baseline CD4+ T-Cell CountsHIV/Hepatitis C Virus-Coinfected Virologic Responders to Pegylated Interferon and Ribavirin Therapy More Frequently Incur Interferon-Related Adverse Events Than Nonresponders DoHepatitis C genotype 3 disease.Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cellsFavorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C.Association of interleukin-15-induced peripheral immune activation with hepatic stellate cell activation in persons coinfected with hepatitis C virus and HIV.Hepatitis C-associated mixed cryoglobulinemic vasculitis induces differential gene expression in peripheral mononuclear cellsTickling the TLR7 to cure viral hepatitis.Rapid development of advanced liver fibrosis after acquisition of hepatitis C infection during primary HIV infection.Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapyInterferon stimulated exonuclease gene 20 kDa links psychiatric events to distinct hepatitis C virus responses in human immunodeficiency virus positive patients.Inteleukin-23 promotes interferon-α responsiveness in hepatitis C virus/HIV-coinfected patientsShort communication: serum-based assay accurately detects single nucleotide polymorphisms of IL28B and SOCS3 in HIV/hepatitis C virus-coinfected subjects.Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patientsImpact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.Strategies to eliminate HBV infection.Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates.HCC surveillance results in earlier HCC detection: results from an Indian cohortMechanisms of alcohol-induced hepatocellular carcinoma.Functional genomics of innate host defense molecules in normal human monocytes in response to Aspergillus fumigatus.Sustained Virologic Response for Chronic Hepatitis C Infection after 27 Days of Treatment with Sofosbuvir and Ribavirin.B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy.Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.MicroRNA expression profiling in HCV-infected human hepatoma cells identifies potential anti-viral targets induced by interferon-αImmune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients.Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C.Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.Altered expression of SHIP, a Toll-like receptor pathway inhibitor, is associated with the severity of liver fibrosis in chronic hepatitis C virus infectionHIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients.Treatment of hepatitis C: a systematic review.Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort studyDifferential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivoDynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.
P50
Q22251066-813C4217-5BC9-4E76-8089-CA064CFA590AQ24657691-D9A8450F-98D3-4BB7-978A-ED1397C17E8FQ24673338-795EAE5A-1D5D-4E84-AEEA-E2329DCD859FQ27481437-55DED3D2-9BF4-4479-8BA9-971789A7FC94Q27490439-7E80940A-52CA-448F-B2FB-0F27FE3A69E5Q27491342-628FAF11-4909-4CF6-B12C-F9D813DB3199Q30244065-13667B9C-9884-4356-951B-982780A3D440Q33285471-E04F500A-685A-4D77-A8DC-41FB9FE32296Q33424681-37F7D8E0-5FE8-4AFD-BCC3-AAE1B9845FBFQ33588960-BED7E444-B598-4948-A6A8-460118E09363Q33664480-CE056D7B-7FC0-4ED8-BE2E-295AA35A8E57Q33690260-D4AD552B-80F9-42F5-B348-2E1927E05DBAQ33889225-D4A53C6E-A583-4181-AD02-50F072509EBCQ33924165-D6FAA8B0-5BE3-4D87-8562-091AA2F71F61Q33968365-541DD1DA-F910-4966-A010-97960741102AQ33988140-FCEE9092-21AE-4312-815C-9FB441F48CB0Q33988201-6D675090-6EA3-4A76-BB00-4F01199F5E9CQ33999004-6A5C7DFF-B400-4A18-B278-6D661CBE45FEQ34075720-A07F3631-02B3-4386-844F-F38F26DD5A61Q34075725-E5DD47F8-8BD9-45E4-B740-9743A4FC7EA2Q34158350-084298A1-245D-497D-B0D0-3B5D948E3FECQ34308129-619480B1-A988-4FAA-9F15-8D266C202FAFQ34389699-7091EFD3-34FB-4E1A-9196-20F79C683FD9Q34401855-EBEC33DC-6492-49D9-A3A9-F3903E41701BQ34449667-B64366DC-8898-4DEF-BDBC-F25587F8382CQ34492766-F43F6FCB-A143-430A-A7CA-1D1817BB72E1Q34520844-BCC8F881-2702-4EEA-B069-D1C72D1A7638Q34541705-05C0DA8F-9C99-4C7A-B577-FE35277CE236Q34588169-5E945CF7-D95E-429E-BA51-3C573076B3FEQ34589553-9673AFC5-D198-4386-A96E-B74C108DA156Q34673075-C3FCF5CD-02AB-442D-BB83-21305745835CQ34725990-C8319E41-1402-40C5-AD1D-8D2652467DDBQ35122536-745F8672-5C21-4030-97C9-21453F44839DQ35164100-8BDABC6E-E061-40CD-8AD5-5E82084C843FQ35214136-96C0BEAC-1254-474C-8877-5AC7374BADC7Q35218240-F5F2A305-8FE2-4874-9550-367B688E895FQ35223637-0406A48F-4145-4071-B865-3376DD051A40Q35592257-206A610E-E064-419E-AF44-56A9266CE02DQ35684549-BF0F36B9-2B03-42F9-A2D5-46ACA904A6FBQ35693436-AEEB0A76-180A-4675-86B4-0EA0266DB094
P50
name
Shyam Kottilil
@en
type
label
Shyam Kottilil
@en
prefLabel
Shyam Kottilil
@en